Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MCC-135 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MCC-135 50 mg BID | EXPERIMENTAL | - |
| MCC-135 100 mg QD | EXPERIMENTAL | - |
| MCC-135 200 mg QD | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MCC-135 | DRUG | MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks |
| Placebo | DRUG | MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks |
Inclusion: * Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. * Having a clinical diagnosis consistent with congestive heart failure, of at least 6 month...
MCC-135 is an investigational small molecule being studied for the treatment of congestive heart failure. It is being developed by Takeda Pharmaceutical Company Limited (TAK). The drug is currently in Phase 2 clinical development and is not yet approved for any use.
MCC-135 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker symbol TAK. The drug is a small molecule in Phase 2 clinical development for congestive heart failure.
MCC-135 is in Phase 2 clinical development. It is an investigational drug for congestive heart failure and has not been approved by regulatory authorities. One Phase 2 clinical trial for the drug has been completed.
MCC-135 has one completed Phase 2 clinical trial, identified as NCT00050076. This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of once and twice daily doses of MCC-135 in 204 subjects with congestive heart failure in the United States.
MCC-135 is not FDA approved. It is an investigational drug in Phase 2 clinical development for congestive heart failure. The completed clinical trial NCT00050076 was a safety and efficacy study, but the drug has not received marketing approval.